Journals / The European Research Journal / 2019 / Cilt: 5 - Sayı: 3

Rivaroxaban-induced acute pancreatitis

Pages
569–571
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this case presentationis to indicate that awareness should be increased regarding the risks of using the drug Rivaroxaban, as it couldlead to drug-induced pancreatitis, even though this is rare.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rivaroxaban is a direct factor Xa inhibitor and has been safely used since 2008.
📊
Key Findings & Data:The case of a 53-year-old female patient that developed in the third month of drug usage wasevaluated, and it was confirmed after a full analysis was conducted that excluded all other factors, such asbiliary calculus, alcohol usage, hypertriglyceridemia, biochemical parameters, ultrasonography and computedtomography that the patient’s condition was caused by the use of Rivaroxaban.
💡
Conclusion & Impact:The aim of this case presentationis to indicate that awareness should be increased regarding the risks of using the drug Rivaroxaban, as it couldlead to drug-induced pancreatitis, even though this is rare.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Rivaroxaban is a direct factor Xa inhibitor and has been safely used since 2008. It is used for the detection ofatrial fibrillation and venous thromboembolism. Pancreatitis is one of the rare but dangerous side effects ofrivaroxaban. The case of a 53-year-old female patient that developed in the third month of drug usage wasevaluated, and it was confirmed after a full analysis was conducted that excluded all other factors, such asbiliary calculus, alcohol usage, hypertriglyceridemia, biochemical parameters, ultrasonography and computedtomography that the patient’s condition was caused by the use of Rivaroxaban. The aim of this case presentationis to indicate that awareness should be increased regarding the risks of using the drug Rivaroxaban, as it couldlead to drug-induced pancreatitis, even though this is rare.

🔖

Cite This Article

Sirkeci, Ö., Sirkeci, E. E., Taşel, B. (2022). Rivaroxaban-induced acute pancreatitis. The European Research Journal, Cilt: 5 - Sayı: 3, 569–571. https://ajindex.com/articles/597766

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am 2008;92:889-923
  2. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis:an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-61. [3]
  3. Tenner S. Drug induced acute pancreatitis: Does it exist? World J Gastroenterol 2014;20:16529-34
  4. Hung WY, Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol 2014;5:405-15.